AR072201A1 - 2-arilaminoquinazolinas para el tratamiento de enfermedades proliferativas - Google Patents
2-arilaminoquinazolinas para el tratamiento de enfermedades proliferativasInfo
- Publication number
- AR072201A1 AR072201A1 ARP090102241A ARP090102241A AR072201A1 AR 072201 A1 AR072201 A1 AR 072201A1 AR P090102241 A ARP090102241 A AR P090102241A AR P090102241 A ARP090102241 A AR P090102241A AR 072201 A1 AR072201 A1 AR 072201A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- ring
- phenyl
- methyl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- -1 piperidin-4-yl-oxyl Chemical group 0.000 abstract 55
- 125000000217 alkyl group Chemical group 0.000 abstract 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 150000002367 halogens Chemical class 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 6
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 abstract 4
- 125000001425 triazolyl group Chemical group 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical class 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 abstract 3
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 abstract 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- 229910052794 bromium Inorganic materials 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005647 linker group Chemical group 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 abstract 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 abstract 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 abstract 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 abstract 1
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 abstract 1
- 125000001246 bromo group Chemical group Br* 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 abstract 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Estos compuestos son inhibidores de PDK1. Tambien se proporcionan composiciones farmaceuticas que incluyen a los compuestos, y metodos para el tratamiento de enfermedades proliferativas, tales como c nceres, con los compuestos o composiciones. Reivindicacion 1: Un compuesto de la formula (1) o una sal farmaceuticamente aceptable del mismo, en donde R1a se selecciona a partir de H y halogeno; R3a se selecciona a partir de heterocicloalquiloxilo C2-6 y heteroarilo C1-6-alcoxilo C1-4; en donde este heterocicloalquiloxilo C2-6 y heteroarilo C1-6-alcoxilo C1-4 est n cada uno opcionalmente sustituidos por un grupo Rw; R4a se selecciona a partir de H, un anillo de tiazol, un anillo de pirazol, un anillo de triazol, un anillo de tetrazol, un anillo de piridina, cicloalquilo C3-6, ciano, halogeno, alquinilo C2-6, heteroarilo C1-6-alquilo C1-4, heteroarilo C1-6-alquinilo C1-4, -C(=O)Ra, y -C(=O)NRbRc; en donde el anillo de tiazol, el anillo de pirazol. el anillo de triazol, el anillo de tetrazol, el anillo de piridina, heteroarilo C1-6-alquilo C1-4 y heteroarilo C1-6-alquinilo C1-4 est n cada uno opcionalmente sustituidos por 1 o 2 grupos Rx'' independientemente seleccionados; Ar1a se selecciona a partir de fenilo opcionalmente sustituido en la posicion meta por un Ry' o, de una manera alternativa, en la posicion para por un grupo Ry''; cada Rw se selecciona independientemente a partir de halogeno, alquilo C1-6, amino, alquilo C1-6-amino, di-alquilo C1-4-amino, alcoxilo C1-6-carbonilo, y alquilo C1-6-carbamilo; en donde este alquilo C1-6, y alquilo C1-6-amino est n cada uno opcionalmente sustituidos por un grupo seleccionado a partir de hidroxilo, alcoxilo C1-6, amino, alquilo C1-6-amino, y di-alquilo C1-4-amino; cada Rx'' se selecciona independientemente a partir de halogeno, hidroxilo, alquilo C1-6, alcoxilo C1-6-carbonilo, y carbamilo; en donde este alquilo C1-6, y alcoxilo C1-6-carbonilo est n cada uno opcionalmente sustituidos por un grupo seleccionado a partir de hidroxilo, amino, alquilo C1-4-amino, y amino-sulfonilo; Ry' se selecciona a partir de halogeno. alcoxilo C1-6, alquilo C1-6, carbamilo, amino-sulfonilo, y alquilo C1-6-sulfonil-amino, en donde este alquilo C1-6, y alcoxilo C1-6 est n cada uno sustituidos por 1 o 2 grupos independientemente seleccionados a partir de hidroxilo, amino, alquilo C1-4-amino, y amino-sulfonilo; Ry'' se selecciona a partir de halo-alquilo C1-6; Ra se selecciona a partir de H, alcoxilo C1-6, y heterocicloalquilo C2-6; Rb se selecciona a partir de H y alquilo C1-6; y Rc se selecciona a partir de alquilo C1-6, cicloalquilo C3-6, heteroarilo C1-6, heterocicloalquilo C2-6, heterocicloalquilo C2-6-alquilo C1-4, y heteroarilo C1-6-alquilo C1-4; en donde este alquilo C1-6 est opcionalmente sustituido por un grupo seleccionado a partir de hidroxilo y alcoxilo C1-4; en el entendido de que: (a) cuando R3a es piperidin-4-il-oxilo o N-metilpiperidin-4-iloxilo, entonces R4 no se selecciona a partir de tiazol-2-ilo, tiazol-4-ilo, tiazol-5-ilo, 5-metil-tiazol-2-ilo, 5-(hidroxi-metil)-tiazol-2-ilo, 5-(hidroxi-metil)-tiazol-4-ilo, piridin-2-ilo, piridin-4-ilo, piridin-3-ilo, 4-metil-piridin-3-ilo, 5-cloro-piridin-4-ilo, 3-metil-piridin-2-ilo, y 1-metil-pirazol-5-ilo; (b) cuando R4a es etinilo y Ar1a es 3-fluoro-fenilo, entonces R3 no se selecciona a partir de piridin-3-il-metoxilo, 6-cloro-piridin-3-il-metoxilo, piridin-2-il-metoxilo, piridin-4-il-metoxilo, 1-(piridin-4-il)-etoxilo, 6-metoxi-piridin-2-il-metoxilo, tiazol-5-il-metoxilo, pirazin-2-il-metoxilo, 5-metil-iso-oxazol-3-ilo, azetidin-3-iloxilo, N-metil-azetidin-3-iloxilo, N-isopropil-azetidin-3-iloxilo. pirrolidin-3-iloxilo, N-metilo, y pirrolidin-3-il-oxilo; (c) cuando R4a es etinilo, entonces Ar1a no se selecciona a partir de 3-(2-hidroxi-propan-2-il)-fenilo, 3-(1-hidroxietil)-fenilo, 3-amino-sulfonil-fenilo, fenilo, 3-(metil-sulfonil-amino)-fenilo, 3-(N,N-dimetil-amino-metil)-fenilo, 3-amino-sulfonil-fenilo, y 3-carbamil-fenilo; (d) cuando R4a es tiazol-2-ilo, entonces Ar1a no se selecciona a partir de 3-(metil-amino-sulfonil)-fenilo, 3-cloro-fenilo, 3-carbamil-fenilo, 3-fluoro-fenilo, 2-(hidroxi-propan-2-il)-fenilo, 1-hidroxi-etilo, 3-amino-sulfonil-fenilo, y fenilo; (e) cuando R4a es tiazol-2-ilo y Ar1a es 3-fluoro-fenilo, entonces R3 no se selecciona a partir de piridin-3-il-metoxilo, 6-cloro-piridin-3-il-metoxilo, 2-cloro-piridin-4-il-metoxilo, 5-metil-iso-oxazol-3-ilo, azetidin-3-iloxilo, N-metil-azetidin-3-iloxilo, N-isopropil-azetidin-3-iloxilo, pirrolidin-3-iloxilo, N-metilo, pirrolidin-3-iloxilo, piperidin-4-iloxilo, y N-metil-piperidin-4-il-oxilo; (f) cuando R4a es bromo, entonces Ar1a no se selecciona a partir de fenilo, 3-fluoro-fenilo, 2-(hidroxi-propan-2-il)-fenilo, 1-hidroxi-etilo, y 3-amino-sulfonil-fenilo; (g) cuando R4a es ciano, entonces R3a no se selecciona a partir de piridin-4-il-metoxilo, piridin-2-il-metoxilo, y 6-metoxi-piridin-2-il-metoxilo; (h) cuando R4a es ciclopropilo, entonces R3a no se selecciona a partir de azetidin-3-il-oxilo; y (i) cuando R4a es hidrogeno, entonces Ar1a es 3-(amino-sulfonil)-fenilo. Reivindicacion 10: Un compuesto de la formula (2) o una sal farmaceuticamente aceptable del mismo, en donde R1 se selecciona a partir de H y halogeno; R2 se selecciona a partir de H, halogeno, y alcoxilo C1-6; R3 se selecciona a partir de H, -OCH2-fenilo, -O-CH2-Het, -OCH2-CH2-Het, y -O-Hy; en donde Het es heteroarilo de 6 miembros que est opcionalmente sustituido por 1 o 2 grupos independientemente seleccionados a partir de hidroxilo, alquilo C1-6, alcoxilo C1-4, amino, alquilo C1-4-amino, di-alquilo C1-4-amino, y alquilo C1-6-carbamilo; Hy es heterocicloalquilo de 6 miembros, el cual est opcionalmente sustituido por 1 o 2 grupos independientemente seleccionados a partir de hidroxilo, alquilo C1-6, alcoxilo C1-4, amino, alquilo C1-4-amino, di-alquilo C1-4-amino, y alquilo C1-6-carbamilo; y fenilo est opcionalmente sustituido por 1 o 2 grupos independientemente seleccionados a partir de hidroxilo, alquilo C1-6, alcoxilo C1-4, amino, alquilo C1-4-amino, di-alquilo C1-4-amino, y alquilo C1-6-carbamilo; R4 se selecciona a partir de ciano, halogeno, alquilo C1-6, alquinilo C2-6, cicloalquilo C3-6, un anillo de tiazol, un anillo de pirazol, y un anillo de piridina; cada uno de los cuales est opcionalmente sustituido por 1 o 2 grupos independientemente seleccionados a partir de hidroxilo, alquilo C1-6, alcoxilo C1-4, amino, alquilo C1-4-amino, y di-alquilo C1-4-amino; en donde este alquilo C1-6 est adem s opcionalmente sustituido por 1 o 2 grupos hidroxilo; Ar1 es una fraccion del grupo de formulas (3), (4), o (5); A es un anillo de pirazol; que est opcionalmente sustituido por 1 o 2 grupos independientemente seleccionados a partir de hidroxilo, alquilo C1-6, alcoxilo C1-4, amino, alquilo C1-4-amino, y di-alquilo C1-4-amino; A' se selecciona a partir de -L2-Ar2 y -L1-Cy1; A'' se selecciona a partir de -L2a-Ar2a y -Cy1a; L1 se selecciona partir de un enlace, -O-, -C(=O)-, -CH2C(=O)-, y -CH2-; en donde el extremo izquierdo del enlazador est unido al anillo de fenilo, y el extremo derecho del enlazador est unido a Cy1; Cy1 se selecciona a partir de un anillo de morfolina, un anillo de tetrahidro-2H-pirano, un anillo de pirrolidina, un anillo de 2-oxo-pirrolidina, y un anillo de piperidina, cada uno de los cuales est opcionalmente sustituido por 1 o 2 grupos independientemente seleccionados a partir de halogeno, hidroxilo, alquilo C1-6, alcoxilo C1-4, amino, alquilo C1-4-amino, di-alquilo C1-4-amino, alquilo C1-6-carbonilo, y alcoxilo C1-6-carbonilo; Cy1a se selecciona a partir de un anillo de morfolina, un anillo de 2-oxo-pirrolidina y un anillo de piperidina; cada uno de los cuales est opcionalmente sustituido por 1 o 2 grupos independientemente seleccionados a partir de halogeno, hidroxilo, alquilo C1-6, alcoxilo C1-4, amino, alquilo C1-4-amino, di-alquilo C1-4-amino, alquilo C1-6-carbonilo, y alcoxilo C1-6-carbonilo; L2 y L2a se seleccionan cada uno independientemente a partir de un enlace, -O-, y -OCH2-; y Ar2 se selecciona a partir de un anillo de pirazol, un anillo de oxazol, un anillo de imidazol, un anillo de triazol, un anillo de tiadiazol, un anillo de piridina, y un anillo de pirimidina; cada uno de los cuales est opcionalmente sustituido con 1, 2 o 3 grupos independientemente seleccionados a partir de hidroxilo, alquilo C1-6, alcoxilo C1-4, amino, alquilo C1-4-amino, y di-alquilo C1-4-amino; Ar2a se selecciona a partir de un anillo de pirazol, un anillo de triazol, un anillo de piridina, y un anillo de pirimidina; cada uno de los cuales est opcionalmente sustituido con 1 o 2 grupos independientemente seleccionados a partir de hidroxilo, alquilo C1-6, alcoxilo C1-4, amino, alquilo C1-4-amino, y di-alquilo C1-4-amino; en el entendido de que: (i) cuando R1 y R2 son cada uno H, R4 es tiazol-2-ilo, R3 es piperidin-4-iloxilo opcionalmente sustituido, y Ar1 es una fraccion del grupo de formula (3), entonces A' no se selecciona a partir de 1,2,4-triazol-1-H-metilo, 1-metil-pirazol-3-ilo, 2-oxo-pirrolidinilo, oxazol-5-ilo, pirazol-1-ilo, 1-metil-1,2,4-triazol-2-ilo, morfolin-4-il-carbonil-metilo, imidazol-2-ilo, 2-metil-tiazol-4-ilo, 1,3,5-trimetil-pirazol-4-ilo, pirimidin-5-ilo, 1,2,4-triazol-1-ilo, 4,5-dimetil-oxazol-2-ilo, pirimidin-5-ilo, 2-metoxi-pirimidin-5-ilo, 6-metoxi-piridin-3-ilo y piridin-3-ilo; (ii) cuando R1 y R2 son cada uno H, Ar1 es una fraccion del grupo de formula (3), A' se selecciona a partir de 1-metil-pirazol-3-ilo, y R3 se selecciona a partir de piridin-3-il-metoxilo y pirazin-2-il-metoxilo, entonces R4 no es tiazol-2-ilo; (iii) cuando R1 y R2 son cada uno H, R4 es tiazol-2-ilo, R3 es piperidin-4-iloxilo opcionalmente sustituido, y Ar1 es una fraccion del grupo de formula (4), entonces A'' no se selecciona a partir de morfolin-4-ilo, morfolin-4-il-carbonil-metilo, pirimidin-5-ilo, y pirazol-1-il-metilo; (iv) cuando R1 y R2 son cada uno H, R4 es bromo, R3 es piridin-3-il-met
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7455608P | 2008-06-20 | 2008-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR072201A1 true AR072201A1 (es) | 2010-08-11 |
Family
ID=40983363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090102241A AR072201A1 (es) | 2008-06-20 | 2009-06-19 | 2-arilaminoquinazolinas para el tratamiento de enfermedades proliferativas |
Country Status (10)
Country | Link |
---|---|
US (1) | US20100121052A1 (es) |
EP (1) | EP2307385A1 (es) |
JP (1) | JP2011524881A (es) |
KR (1) | KR20110026485A (es) |
CN (1) | CN102123991A (es) |
AR (1) | AR072201A1 (es) |
AU (1) | AU2009259358A1 (es) |
BR (1) | BRPI0914614A2 (es) |
CA (1) | CA2727251A1 (es) |
WO (1) | WO2009153313A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2762466T (pt) | 2011-09-29 | 2017-07-31 | Ono Pharmaceutical Co | Derivado de fenilo |
KR102219695B1 (ko) | 2013-03-15 | 2021-02-25 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
UA120248C2 (uk) | 2013-03-15 | 2019-11-11 | Селджен Кар Ллс | Гетероарильні сполуки та їх застосування |
EP2980072B1 (en) | 2013-03-26 | 2018-04-25 | ONO Pharmaceutical Co., Ltd. | Phenyl derivative |
WO2017015152A1 (en) | 2015-07-17 | 2017-01-26 | Memorial Sloan-Kettering Cancer Center | Combination therapy using pdk1 and pi3k inhibitors |
US10344033B2 (en) | 2015-10-02 | 2019-07-09 | Sentinel Oncology Limited | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors |
CN108329330B (zh) * | 2017-01-20 | 2021-05-04 | 复旦大学 | 2-苄氧苯基噁唑并吡啶类化合物及其药物用途 |
KR20200094734A (ko) | 2017-09-22 | 2020-08-07 | 주빌런트 에피파드 엘엘씨 | Pad 억제제로서의 헤테로사이클릭 화합물 |
MX2020003341A (es) | 2017-10-18 | 2020-09-17 | Jubilant Epipad LLC | Compuestos de imidazo-piridina como inhibidores de pad. |
JP7279057B6 (ja) | 2017-11-06 | 2024-02-15 | ジュビラント プローデル エルエルシー | Pd1/pd-l1活性化の阻害剤としてのピリミジン誘導体 |
EP3704120B1 (en) | 2017-11-24 | 2024-03-06 | Jubilant Episcribe LLC | Heterocyclic compounds as prmt5 inhibitors |
MX2020009517A (es) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1. |
CN111170986A (zh) * | 2018-11-13 | 2020-05-19 | 北京睿熙生物科技有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
CN116731046A (zh) * | 2020-10-28 | 2023-09-12 | 杭州阿诺生物医药科技有限公司 | 一种高活性的hpk1激酶抑制剂 |
WO2023138412A1 (en) * | 2022-01-20 | 2023-07-27 | Insilico Medicine Ip Limited | Fused pyrimidin-2-amine compounds as cdk20 inhibitors |
KR20230153951A (ko) * | 2022-04-29 | 2023-11-07 | 보로노이 주식회사 | 헤테로아릴 유도체 화합물 및 이의 용도 |
WO2023218241A1 (en) * | 2022-05-13 | 2023-11-16 | Voronoi Inc. | Heteroaryl derivative compounds, and pharmaceutical composition comprising thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR060358A1 (es) * | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
EA200900819A1 (ru) * | 2006-12-22 | 2010-02-26 | Новартис Аг | Хиназолины для ингибирования pdk1 |
-
2009
- 2009-06-09 US US12/456,032 patent/US20100121052A1/en not_active Abandoned
- 2009-06-18 CA CA2727251A patent/CA2727251A1/en not_active Abandoned
- 2009-06-18 WO PCT/EP2009/057606 patent/WO2009153313A1/en active Application Filing
- 2009-06-18 EP EP09765892A patent/EP2307385A1/en not_active Withdrawn
- 2009-06-18 KR KR1020117001354A patent/KR20110026485A/ko not_active Application Discontinuation
- 2009-06-18 CN CN2009801320767A patent/CN102123991A/zh active Pending
- 2009-06-18 JP JP2011514043A patent/JP2011524881A/ja active Pending
- 2009-06-18 AU AU2009259358A patent/AU2009259358A1/en not_active Abandoned
- 2009-06-18 BR BRPI0914614A patent/BRPI0914614A2/pt not_active IP Right Cessation
- 2009-06-19 AR ARP090102241A patent/AR072201A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2727251A1 (en) | 2009-12-23 |
EP2307385A1 (en) | 2011-04-13 |
CN102123991A (zh) | 2011-07-13 |
BRPI0914614A2 (pt) | 2019-09-24 |
JP2011524881A (ja) | 2011-09-08 |
AU2009259358A1 (en) | 2009-12-23 |
WO2009153313A1 (en) | 2009-12-23 |
US20100121052A1 (en) | 2010-05-13 |
KR20110026485A (ko) | 2011-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR072201A1 (es) | 2-arilaminoquinazolinas para el tratamiento de enfermedades proliferativas | |
ES2250186T3 (es) | Inhibidores de tirosina quinasa. | |
AU2006290814B2 (en) | 2-aniline-4-aryl substituted thiazole derivatives | |
ES2255621T3 (es) | Inhibidores de tirosina quinasa. | |
JP2019504821A (ja) | ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン | |
RU2481333C2 (ru) | Производные 1,1,1-трифтор-2-гидрокси-3-фенилпропана | |
JP2014525444A5 (es) | ||
EA028626B1 (ru) | БЕНЗИМИДАЗОЛЫ, МОДУЛИРУЮЩИЕ TNF-α | |
HRP20180382T1 (hr) | Inhibitori protein kinaze | |
JP2018535999A5 (es) | ||
IL187690A (en) | Derivatives 1, 2, 4 - Triazolo - 1, 6 - Naphthiridines as inhibitors of AKT activity for use in the preparation of drugs for the treatment of cancer | |
RU2019118623A (ru) | Пирролопиримидины в качестве потенциаторов мвтр | |
JP2009536196A5 (es) | ||
JP2018524331A5 (es) | ||
JP2010513272A5 (es) | ||
JP2005511608A5 (es) | ||
JP2015533157A5 (es) | ||
HRP20131210T1 (hr) | Heteroaromatski aril triazol derivati kao inhibitori pde10a enzima | |
JP2012502099A5 (es) | ||
IL148891A (en) | History of indole, pharmaceutical preparations containing them and their use in the preparation of medicines | |
RU2014152625A (ru) | Конденсированные с гетероарилкетонами азадекалины - модуляторы глюкокортикоидных рецепторов | |
HRP20160539T1 (hr) | Antagonisti trpv4 | |
IL263511A (en) | H1-pyrazolo[4, 3-b]pyridines as pde1 inhibitors | |
EA029718B1 (ru) | Бифтордиоксалан-аминобензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс | |
JP2006507302A (ja) | キナーゼ阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |